Pages
Products
AAV5-GFAP-GFP

AAV5-GFAP-GFP

Cat.No. :  AAV00195Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 5 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00195Z
Description AAV serotype 5 particles contain GFP under GFAP promoter for specific expression in astrocytes/glial cells.
Reporter GFP
Serotype AAV Serotype 5
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Recombinant adeno-associated virus (AAV) vectors are currently considered the leading platform for in vivo gene therapy. Since the first isolation of infectious AAV clones, there has been a great deal of effort to improve this virus as a gene therapy vector. AAV vectors have become increasingly popular over the years for a number of reasons, including the lack of pathogenicity of wild-type AAV, low immunogenicity, and the existence of different serotypes with broad but distinct tropisms and the ability to transduce a variety of target tissues, including the liver, retina, myocardium, and central nervous system. These aspects, along with the numerous innovations established over the years, have fueled the study of AAV as a platform for human gene therapy. Although initially explored for the delivery of genes mutated in monogenic genetic diseases, AAV vectors have since been adapted to target more complex conditions or to deliver innovative tools, such as those for genome editing. More than three decades of preclinical research culminated in three AAV-based gene therapy products for the treatment of genetic diseases affecting different tissues that received market approval from the European Medicines Agency and the U.S. Food and Drug Administration between 2012 and 2019.

Feeding behavior is a complex process that depends on the brain's ability to integrate hormonal and nutrient signals, such as glucose. One glucose-sensing mechanism relies on the glucose transporter 2 (GLUT2) in the hypothalamus, particularly in radial glia-like cells, called tanycytes. Here, researchers analyzed whether a GLUT2-dependent glucose-sensing mechanism is required for the normal regulation of feeding behavior in GFAP-positive tanycytes. Genetic inactivation of Glut2 in GFAP-expressing tanycytes was performed using Cre/Lox technology. The efficiency of GFAP-tanycyte targeting in the anterior-posterior and dorso-ventral axes was analyzed by assessing GFP fluorescence. Feeding behavior, hormone levels, neuronal activity using c-Fos, and neuropeptide expression were also analyzed during the transition from fasting to refeeding. Under basal conditions, mice with Glut2 inactivation had normal food intake and meal patterns. Imposing a pre-fasting period resulted in a reduction in total food intake and delayed meal times during the refeeding period. Furthermore, Glut2 inactivation increases the number of c-Fos-positive cells in the ventromedial nucleus in response to fasting and deregulates Pomc expression during the transition from fasting to resumption of feeding.Thus, GLUT2-dependent glucose-sensing mechanisms in GFAP-tanycytes are necessary to control food consumption and promote meal timing after a fasting period.

To delete the Glut2 gene Slc2a2loxP/loxp from GFAP-positive elongated cells in zones 1 to 6, adeno-associated virus serotype 5 (AAV5)-Gfap-Cre-GFP and control viral vector AAV5-Gfap-GFP were stereotaxically injected in 3V, where GFAP-expressing elongated cells project to the DMN, VMN, and ARC in similar proportions (Figure 1A). Injection of AAV5-Gfap-CRE-GFP induced the expected recombination of the Glut2 allele (Figure 1B). The presence of the non-recombined floxed allele corresponding to the 281 bp product is due to the presence of non-transduced cells in this zone. To confirm that recombination occurred only in elongated cells, the GFP signal and the percentage of GFAP/GFP-positive elongated cells in the hypothalamus of mice transduced for 2 weeks were assessed by confocal microscopy. As expected, GFP was detected in the apical region and processes of elongated cells (Figure 1C, arrows). In addition, GFP fluorescence (green) was observed in GFAP-positive elongated cells (yellow, arrows), which contained button-shaped endfeet and were in close contact with other cells present in the hypothalamic parenchyma (Figure 1D, arrows). To determine the percentage of transduction, the number of GFAP-expressing elongated cells positive for GFP fluorescence was quantified. As shown in Figure 1E, the percentage of GFAP-expressing elongated cells positive for GFP fluorescence was close to 28.5%. In all analyzed sections, only one GFAP-positive astrocyte was detected to be transduced.

Glut2 gene inactivation in GFAP-expressing tanycytes and its in situ evaluation.Figure 1. Glut2 gene inactivation in GFAP-expressing tanycytes and its in situ evaluation. (Barahona M J, et al., 2022)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Bright and Clear Fluorescence

We used the AAV5-GFAP-GFP in our recent astrocyte labeling experiment, and the results were phenomenal. The GFP expression was incredibly bright and clear, making cell visualization and imaging straightforward and less time-consuming.

United Kingdom

07/24/2022

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction